by myhealthteam | Oct 21, 2024 | Uncategorized
By Eric Peacock, Co-founder and CEO, MyHealthTeam R&D in rare diseases has skyrocketed. Thirty percent of today’s R&D pipeline is in rare diseases, and 40 percent of overall pipeline growth since 2013 is due to rare diseases. As the leading creator of patient...
by Jessica Meylikhov | Oct 18, 2024 | Uncategorized
Por Mary Ray, cofundadora y jefa de operaciones, MyHealthTeam La importancia de las redes de apoyo inclusivas y culturalmente sensibles es innegable. Por ejemplo, datos de la Oficina del Censo de los Estados Unidos muestran que la cantidad de personas en los EE. UU....
by Jessica Meylikhov | Oct 18, 2024 | Uncategorized
By Mary Ray, Co-founder & COO, MyHealthTeam The importance of inclusive and culturally sensitive support networks cannot be overstated. For example, data from the U.S. Census Bureau shows the number of people in the U.S. who speak Spanish at home has increased by...
by Jessica Meylikhov | Oct 16, 2024 | Uncategorized
By Eric Peacock, CEO and Co-founder, MyHealthTeam Health care marketing is rapidly evolving, driven by AI, health privacy legislation, the need to reach more diverse patient communities, and the growth of direct-to-patient offerings. To help us sort the reality from...
by Jessica Meylikhov | Jun 25, 2024 | Uncategorized
By Eric Peacock, Co-founder and CEO, MyHealthTeam At MyHealthTeam’s all-company get-together in Nashville, we invited five pharma marketing experts from top agencies and biotechs to join me on a panel. We discussed the “New Marketing Playbook” for everything from rare...
by Jessica Meylikhov | Jun 13, 2024 | Uncategorized
The Reuters Pharma USA conference, held this spring in Philadelphia, is one of the best conferences attended by and featuring pharma executives. Here are our notes on some of the top themes and actionable takeaways from the event. 1. Diversity and Inclusion in Pharma ...
